ライフサイエンスコーパス: DNA vaccine

1 ly improved the antibody response to the H+F DNA vaccine.

2 nce of a simian immunodeficiency virus (SIV) DNA vaccine.

3 zation was followed by administering Bla g 1 DNA vaccine.

4 istered alone or in combination with the JS7 DNA vaccine.

5 halable dry powder, and early administration DNA vaccine.

6 /-), recipient mice to respond better to the DNA vaccine.

7 uvants did not enhance immunogenicity of the DNA vaccine.

8 une responses despite multiple high doses of DNA vaccine.

9 igen presentation relative to a control scFv DNA vaccine.

10 ost efficacy when using the IL-12(High)/F1-V DNA vaccine.

11 p41, even with 1% of the dose of nontargeted DNA vaccine.

12 compared to an equal dose of a conventional DNA vaccine.

13 mmunized by a single injection with a unique DNA vaccine.

14 ent protein in vitro than did a conventional DNA vaccine.

15 s showing efficacy with an FIV-pPPRDelta vif DNA vaccine.

16 nt vesicular stomatitis virus (mtdVSV) and a DNA vaccine.

17 y than active vaccination with an anti-CHIKV DNA vaccine.

18 he Marburgvirus Angola strain expressed in a DNA vaccine.

19 pproach to enhance the immunogenicity of the DNA vaccine.

20 ther oral insulin or a proinsulin-expressing DNA vaccine.

21 ocyte responses in mucosal compartments than DNA vaccines.

22 articles (VLPs) and the simplicity of use of DNA vaccines.

23 g properties essential to generate effective DNA vaccines.

24 HIV gag to mice successively as protein and DNA vaccines.

25 an ongoing challenge for the development of DNA vaccines.

26 radermal injection using optimized synthetic DNA vaccines.

27 ds for enhancing immune responses to plasmid DNA vaccines.

28 substantially improves the immunogenicity of DNA vaccines.

29 the immunity and protection that result from DNA vaccines.

30 (Low)/F1, IL-12(Low)/V, or IL-12(Low) vector DNA vaccines.

31 Ad5) has frequently been used as a boost for DNA vaccines.

32 and therefore the immunogenicity of plasmid DNA vaccines.

33 making them attractive candidate vectors for DNA vaccines.

34 imeric CD40L and GITRL are new adjuvants for DNA vaccines.

35 an increase the magnitude of the response to DNA vaccines.

36 ich is mainly activated by the CpG motifs of DNA vaccines.

37 cells (DCs) attenuates antitumor effects of DNA vaccines.

38 ach endowing immunomodulatory properties for DNA vaccines.

39 vo delivery to enhance the immunogenicity of DNA vaccines.

40 absent in melanoma 2 (Aim2) as a sensor for DNA vaccines.

41 e induced by 2 immunizations with sGP and GP DNA vaccines.

42 n shaping the Ag-specific immune response to DNA vaccines.

43 c CD8 T cells induced by subunit (peptide or DNA) vaccines.

44 immunogenicity of (1) a 4-dose regimen of a DNA vaccine, (2) a 3-dose priming regimen of the DNA vac

45 uated the safety and immunogenicity of these DNA vaccines (4 mg administered intramuscularly by Bioje

46 the amount of IL-12 produced by the two F1-V DNA vaccines, Ab responses and Th cell responses to F1-

47 To determine whether the candidate DNA vaccine ADVAX could induce similar responses, we ana

48 Combination of dMAb and the CHIKV DNA vaccine afforded rapid and long-lived protection.

49 host factors that restrict long-term plasmid DNA vaccine Ag expression in vivo.

50 lls induce Fas-mediated apoptosis of plasmid DNA vaccine Ag-expressing cells.

51 The DNA vaccine alone or as a priming regimen for the Ad5 va

52 me the capacity of a single high dose of HIV DNA vaccine alone to induce long-lasting and polyfunctio

53 rolled infection than the group treated with DNA vaccine alone.

54 form and have previously shown that improved DNA vaccines alone are capable of inducing both binding

55 alities [anticancer vaccination, TC1 (HPV E7 DNA vaccine), alphaPD-1, and MC38] and found that CAFs b

56 The IL-13Ralpha2 DNA vaccine also exhibited antitumor activity against es

57 lomavirus 16 (HPV16)-targeted version of the DNA vaccine also induced L2 antibodies and protected mic

58 l of 299 individuals received 2 doses of JS7 DNA vaccine and 2 doses of MVA/HIV62B at 0, 2, 4, and 6

59 A plasmid DNA vaccine and a single-shot recombinant rhesus adenovi

60 e-VRP boost regimen (DDV) using two doses of DNA vaccine and a third dose of VRP vaccine.

61 Furthermore, mice immunized with Pfs25 DNA vaccine and challenged with TrPfs25Pb displayed redu

62 n influence on the immune response to an SIV DNA vaccine and decreased the vaccine's efficacy.

63 8(+) T cell immunity develop to a subsequent DNA vaccine and improved protection to intranasal challe

64 oost strategies comprising multiple doses of DNA vaccine and recombinant viral vectors.

65 ngly upregulated only in the presence of the DNA vaccine and trends to positively correlate with seve

66 Increased potency of DNA vaccines and reduced vector immunity may ultimately

67 he ProstVac poxviral vaccine, a PAP-encoding DNA vaccine, and immune checkpoint inhibitory approaches

68 ign of retroviral vectors for transfections, DNA vaccines, and gene therapy.

69 g modified protein immunotherapy, adjuvants, DNA vaccines, and helminth administration.

70 ytokines have modulated immunity elicited by DNA vaccines, and replication-competent Ad-recombinant p

71 demonstrate that CD4(+) T cells facilitated DNA vaccine antigen clearance in a Fas/FasL-dependent ma

72 4(+) T cell-mediated cytotoxicity in plasmid DNA vaccine antigen clearance.

73 ayed the crucial role in attenuating plasmid DNA vaccine antigen expression.

74 pes responsible for the clearance of plasmid DNA vaccine antigens are not known.

75 5 boost (10(10) particle units) encoding all DNA vaccine antigens except Nef.

76 g cellular and humoral responses against the DNA vaccine antigens, which included Gag, Pol, Env, Nef,

77 t the preclinical assessment of an optimized DNA vaccine approach that targets four P. falciparum ant

78 hese findings support the concept of using a DNA vaccine approach to generate a potent pan-arenavirus

79 4gp140 antigen when cation-complexed plasmid DNA vaccines are applied topically to the murine pulmona

80 e (LNP)-formulated Andes virus or Zika virus DNA vaccines are elevated over unformulated vaccine.

81 Methods to increase the immunogenicity of DNA vaccines are needed.

82 HIV DNA vaccines are potent inducers of cell-mediated immune

83 etic anti-Ebola virus glycoprotein (EBOV-GP) DNA vaccines as a strategy to expand protective breadth

84 The For t 2 DNA vaccine at 50 mug prevented the production of For t

85 ne in mice that had been primed by GP or sGP DNA vaccine augmented the levels of anti-GP antibody res

86 ion was achieved using a multivalent epitope DNA vaccine based on epitope selection from cottontail r

87 t protein analogs of the expressed genes and DNA vaccines based on the multigene clusters have been s

88 own to augment the immunogenicity of plasmid DNA vaccines, but its mechanism of action has not been f

89 improved the immunogenicity of HA-expressing DNA vaccines by using codon-optimized HA sequences for e

90 nstration that a Sindbis virus-based measles DNA vaccine can elicit robust MV immunity in neonates by

91 mized IL-15 immune adjuvant delivered with a DNA vaccine can impact the cellular immune profile in no

92 inhibitor to the TME, combined with an HER-2 DNA vaccine can improve immune surveillance against HER-

93 This study tested whether the For t 2 DNA vaccine can prevent allergic symptoms in For t 2-sen

94 Immunotherapy using For t 2 DNA vaccine can protect mice from being sensitized by mi

95 Thus, the immunogenicity of DNA vaccines can be augmented with TLR9-L plus FL.

96 s a proof-of-concept that LNP formulation of DNA vaccines can be used to produce more potent active v

97 the discovery of DNA vaccines >20 y ago that DNA vaccines can function as adjuvants.

98 BDES, which functions as both a subunit and DNA vaccine, can offer a promising multistage vaccine ca

99 In this study, we developed a series of DNA vaccine candidates expressing different forms of the

100 pe-specific dengue virus serotype 2 (DENV-2) DNA vaccine candidates were evaluated for their immunoge

101 -mimicking shikimoyl headgroup are promising DNA vaccine carriers for dendritic cell (DC) transfectio

102 DNA vaccines coexpressing antigen and an expressed RNA (

103 nd efficacy of a cytomegalovirus therapeutic DNA vaccine compared with placebo.

104 responses when administered 2 days after the DNA vaccine, compared with simultaneous administration.

105 uenza challenge model we show that a plasmid DNA vaccine complexed to a less toxic form of PEI called

106 y, immunogenicity, and protection by testing DNA vaccines comprised of GP genes with deleted N-linked

107 potential of DC-mediated immunization with a DNA vaccine consisting of HIV-1-p55gag (gag, group-speci

108 A DNA vaccine containing an HLA-A2.1-restricted human papi

109 dengue virus type 2 (DENV-2) vaccines: (i) a DNA vaccine containing the prM-E gene region (D), (ii) a

110 These results suggest that MHC II-targeted DNA vaccines could play a role in situations of pandemic

111 ted and tested in conjunction with a plasmid DNA vaccine (D1ME-DNA) expressing identical dengue virus

112 synthetic, multivalent, highly concentrated, DNA vaccine delivered by a minimally invasive, novel ski

113 ine elicited higher antibody titers than the DNA vaccine delivered with EP, T-cell response rates wer

114 DNA vaccines delivered with electroporation (EP) have sh

115 Multiple-injection regimens of the EBOV-GP DNA vaccine, delivered by intramuscular administration f

116 ting of dendritic cells is an ideal goal for DNA vaccine delivery in order to stimulate both arms of

117 To better understand the details of DNA vaccine delivery in vivo, we prepared polymer/DNA co

118 of PEI could be utilised for topical plasmid DNA vaccine delivery to human mucosal tissue surfaces, a

119 leic acid transfection reagents in vitro and DNA vaccine delivery vehicles in vivo.

120 y illustrates a new pathway of polymer-based DNA vaccine delivery via bystander cells without direct

121 how cationic polymers could be optimized for DNA vaccine delivery.

122 bacteria are promising candidate vectors for DNA vaccine delivery.

123 nella vaccine (RASV) strain into a universal DNA vaccine-delivery vehicle, our approach was to geneti

124 immunization of mice with a single dose of a DNA vaccine derived from pathogenic SHIV(KU2) (Delta4SHI

125 We report here a novel concept for DNA vaccine design that exploits the unique and powerful

126 whole, the data suggested that while the gag DNA vaccine did not prime detectable early CTL responses

127 studies demonstrate how rationally designed DNA vaccines directed against self antigens for enhanced

128 The DENV DNA vaccine directs the synthesis and assembly of virus-

129 The DNA vaccine-duck/egg system can be scaled as needed and

130 cacy of any antiviral product produced using DNA vaccine-duck/egg system.

131 This DNA vaccine elicited T cell responses of greater magnitu

132 These CD40L-augmented DNA vaccines elicited strong CD8(+) T-cell responses but

133 oaches to enumerate disease-related T cells, DNA vaccines, eliciting responses to pre-assembled MHC-p

134 We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolo

135 he gene gun administration of CIITA DNA with DNA vaccines employing different strategies to improve M

136 To determine this, we generated a DNA vaccine encoding a fusion protein comprised of the v

137 In addition, a DNA vaccine encoding an HIV gag p41-scFv DEC205 fusion p

138 After a single i.m. injection of the DNA vaccine encoding an HIV gag p41-scFv DEC205 fusion p

139 Some mice were given a DNA vaccine encoding an immunogenic M. tuberculosis prot

140 We found that immunization of mice with a DNA vaccine encoding BAFF or APRIL multitrimers, togethe

141 The capacity of multi subunit DNA vaccine encoding different stage Plasmodium antigens

142 esus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140.

143 ults of a phase I/IIa trial conducted with a DNA vaccine encoding human PAP in patients with stage D0

144 dendritic cells (DCs) and were primed with a DNA vaccine encoding immunodeficiency virus antigens mix

145 A DNA vaccine encoding influenza WSN virus HA antigen deli

146 nded these studies by delivering a synthetic DNA vaccine encoding Leishmania glycosomal phosphoenolpy

147 This study is the first to demonstrate that DNA vaccine encoding midge allergen is effective in prev

148 A plasmid DNA vaccine encoding mouse proinsulin II reduced the inc

149 We have previously demonstrated that a DNA vaccine encoding PAP can elicit antigen-specific CD8

150 The demonstration that a DNA vaccine encoding PAP is safe, elicits an antigen-spe

151 om prostate cancer patients immunized with a DNA vaccine encoding prostatic acid phosphatase (PAP) an

152 ion were then vaccinated 4 times with an SIV DNA vaccine encoding SIVgag, SIVpol, and SIVenv.

153 f mice that were previously immunized with a DNA vaccine encoding the P. berghei sexual-stage antigen

154 A single-plasmid DNA vaccine encoding the premembrane and the envelope gl

155 A DNA vaccine encoding the protein premembrane and the E g

156 we report that administration of a synthetic DNA vaccine encoding ZIKV pre-membrane and envelope (prM

157 ses elicited by Sindbis virus replicon-based DNA vaccines encoding measles virus (MV) hemagglutinin (

158 Using three novel HCV DNA vaccines encoding non-structural proteins NS4B, NS5A

159 Previously, DNA vaccines encoding proteins that target Ag to MHC cla

160 Genetic technology allows construction of DNA vaccines encoding selected tumor antigens together w

161 Plasmid DNA vaccines encoding the fusion genes generated robust

162 We developed two Sindbis virus DNA vaccines encoding the measles virus hemagglutinin (p

163 The immunogenicity of DNA vaccines encoding three RhCMV proteins (a truncated

164 Delivery of DNA vaccines encoding XBP1 and tumor Ag to skin DC resul

165 study data have re-established the value of DNA vaccines, especially in priming high-level Ag-specif

166 Encapsulation of plasmid DNA vaccine expressing IBV nucleocapsid (N) protein by t

167 We demonstrated that priming with a DNA vaccine expressing only the HIV Env V1V2 region indu

168 Mice immunized with a DNA vaccine expressing simian immunodeficiency virus Gag

169 Here, we show that recombinant VSV and DNA vaccines expressing NS1, alone, confer partial prote

170 We assessed two new DNA vaccines expressing premembrane and envelope Zika vi

171 The 6-plasmid DNA vaccine (expressing clade B Gag, Pol, and Nef and En

172 These studies advance the DNA vaccine field and provide a novel, more tolerable va

173 BHT-3009 is a tolerizing DNA vaccine for MS, encoding full-length human myelin ba

174 of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or com

175 DNA vaccines formulated with the cationic lipid-based ad

176 oved for human use (VR1020), an Sm-p80-based DNA vaccine formulation confers a 46% reduction in the w

177 Both forms of HA DNA vaccines, from either H1 or H3 serotypes, were able

178 However, 2 immunizations with GP but not sGP DNA vaccine fully protected mice from lethal challenge.

179 to dsDNA, potentially impacting responses to DNA vaccines, gene therapy, and autoimmune disease patho

180 It has been known since the discovery of DNA vaccines >20 y ago that DNA vaccines can function as

181 During the Mexican flu pandemic, a targeted DNA vaccine (HA from A/California/07/2009) was generated

182 Next, a DNA vaccine has been evaluated in men with biochemically

183 monstrated in a clinical trial and a similar DNA vaccine has been licensed for use in horses.

184 glycoprotein (GP); protein-based subunit and DNA vaccines have been tested with moderate success.

185 DNA vaccines have been very poorly immunogenic in humans

186 DNA vaccines have many potential benefits but have faile

187 DNA vaccines have recently emerged at the forefront of a

188 However, DNA vaccines have thus far fallen short of expectations,

189 Thus, the incorporation of FMGs into DNA vaccines holds promise for the successful control of

190 DNA vaccine immunogenicity has been limited by inefficie

191 microneedle patch vaccination using a rabies DNA vaccine in dogs.

192 unogenicity of the GLS-5300 MERS coronavirus DNA vaccine in healthy adults.

193 eport the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study.

194 to a human immunodeficiency virus type 1 Env DNA vaccine in mice and allowed a 10-fold reduction in v

195 Boosting with sGP or GP DNA vaccine in mice that had been primed by GP or sGP DN

196 pe immunodominance hierarchies elicited by a DNA vaccine in mice.

197 rmal injection and EP of the auxoGTUmultiSIV DNA vaccine in nonhuman primates.

198 ogenicity and efficacy of a TcdA/B RBD-based DNA vaccine in preclinical models of acute toxin-associa

199 for our simian immunodeficiency virus (SIV) DNA vaccine in rhesus macaques.

200 cond, we demonstrate the crucial role of the DNA vaccine in soluble factors release, such as MCP-1 or

201 We used DKK1-DNA vaccine in the murine MOPC-21 myeloma model, and the

202 We have developed in this study a novel DNA vaccine in which viral hemagglutinin (HA) is bivalen

203 ted the involvement of Aim2 as the sensor of DNA vaccines in eliciting Ag-specific Ab responses.

204 ur understanding on the potential utility of DNA vaccines in generating Ag-specific immune responses.

205 tion of immune responses (IR) induced by HIV DNA vaccines in humans is one of the great challenges in

206 tractive strategy for increasing efficacy of DNA vaccines in larger animals and humans.

207 -boost immunization regimens with GP and sGP DNA vaccines in mice and their efficacy against lethal E

208 of mtdVSV-NS1-based vaccine or two doses of DNA vaccine induced high levels of NS1-specfic antibody

209 The DNA/DNA vaccine induced humoral responses comparable to thos

210 These 'multilayer tattoo' DNA vaccines induced immune responses against a model HI

211 signaling pathways is an approach to improve DNA vaccine-induced adaptive immunity for infectious dis

212 The magnitude and durability of a plasmid DNA vaccine-induced immune response is shaped by immune

213 emonstrated the requirement of type I IFN in DNA vaccine-induced immune responses via the Aim2 pathwa

214 tes a critical role for NKT cells in plasmid DNA vaccine-induced immune responses.

215 ndicate a previously unreported link between DNA vaccine-induced pyroptotic cell death and vaccine im

216 ed to CD4(+) T lymphocytes within a model of DNA vaccine-induced tumor immunity to Tag-expressing tum

217 Our results showed that DNA vaccine-induced, Irf7-dependent signaling, as part o

218 ating that the potent priming induced by the DNA vaccine initially framed the immune responses in suc

219 ble Salmonella endosomal escape to release a DNA vaccine into the cytosol, and to decrease Salmonella

220 Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages

221 However, the DNA vaccine is required to strongly upregulate several g

222 e that the limited immunogenicity of plasmid DNA vaccines is the result, at least in part, of the rap

223 Here we describe the development of a SFTSV DNA vaccine, its immunogenicity, and its protective effi

224 g that the fusion protein (administered as a DNA vaccine) maintained the immunogenicity of both PdSP1

225 on of BALB/c mice indicated that hepatitis B DNA vaccine/Man-CS-Phe polyplexes not only induced multi

226 n humans, human immunodeficiency virus (HIV) DNA vaccines may need to include immunostimulatory adjuv

227 DNA vaccines offer promising strategies for immunization

228 ty and immunogenicity of two investigational DNA vaccines, one (EBO vaccine) encoding Ebola virus Zai

229 ents including vaccine adjuvants (Vaxjo) and DNA vaccine plasmids (DNAVaxDB).

230 ificant improvement in the efficiency of the DNA vaccine platform, resulting in immune responses that

231 whether a combination of GX-188E therapeutic DNA vaccine plus pembrolizumab showed antitumour activit

232 DNA has been shown to enhance the potency of DNA vaccines, possibly by facilitating uptake of the pla

233 This demonstrates that DNA vaccine potency may be augmented by the incorporatio

234 mprove MHC I and II processing could enhance DNA vaccine potency.

235 mouse T cell response to vaccinia virus or a DNA vaccine potentiated antigen-specific CD8(+) memory T

236 east tumors and, when combined with an HER-2 DNA vaccine, prevented HER-2(+) primary tumor recurrence

237 BAPCs were tested for in vivo delivery of a DNA vaccine previously designed to activate immune respo

238 A variety of DNA vaccine prime and recombinant viral boost immunizati

239 accination of BALB/c mice with an i.m. HBsAg-DNA vaccine prime followed by an intranasal boost with H

240 ing antibodies in rabbits (following a gp120 DNA vaccine prime) and that the antisera competed with b

241 In contrast, DNA vaccine priming did not further improve the protecti

242 a rMVA vaccine administered with and without DNA vaccine priming METHODS: GeoVax pGA2/JS7 DNA (D) and

243 Four DNA vaccine products have recently been approved, all in

244 DNA vaccines promote an immune response by providing ant

245 Although the DNA vaccine provided comparable efficacy against vertica

246 rted the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid

247 deficiency virus type 1 (HIV-1) PENNVAX(R)-B DNA vaccine (PV) is a mixture of 3 expression plasmids e

248 , followed by parenteral boosting with PfCSP DNA vaccines pVR2510 and pVR2571.

249 d boosted intradermally on day 56 with PfCSP DNA vaccine pVR2571 induced high titers of serum NANP im

250 erformed detailed assessment of an HIV-1 gag DNA vaccine recipient (subject 00015) who was previously

251 ic) amounts of helper antigen plasmid into a DNA vaccine regimen dramatically increased T cell-depend

252 These potential advantages of DNA vaccines remain unrealized due to a lack of efficacy

253 nation of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to

254 c immunization of mice with the IL-13Ralpha2 DNA vaccine resulted in protection against D5alpha2 tumo

255 In fact, a legumain-based DNA vaccine served as a tool to prove this point, as it

256 dition, antibody induced by the IL-13Ralpha2 DNA vaccine showed a modest but significant inhibitory e

257 dings demonstrate that the route and dose of DNA vaccines significantly impact the quality of immune

258 demonstrate that immunization with a CFP-10 DNA vaccine stimulates a specific T-cell response only t

259 sociated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP

260 We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) pro

261 These data demonstrated that DNA vaccines targeting the RhCMV homologues of HCMV gB a

262 Our findings demonstrate that use of the DNA vaccine technology could be used to produce candidat

263 se data demonstrate the feasibility of using DNA vaccine technology coupled with the duck/egg system

264 Second, we used DNA vaccine technology to manufacture a polyclonal immun

265 VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphop

266 ing a candidate preventive/therapeutic naked-DNA vaccine that expresses human calreticulin (hCRT) fus

267 en with self-antigens could produce a potent DNA vaccine that may be applicable to other tumor-associ

268 In this study, we describe two novel DNA vaccines that as proteins target HLA class II (HLA-I

269 ome immune tolerance to HER-2, we formulated DNA vaccines that express both human HER-2 and heterolog

270 DNA vaccines that target prostate-specific antigen and p

271 The efficacy of DNA vaccines therefore may be enhanced by inclusion of s

272 induced pyroptosis/apoptosis that allows the DNA vaccine time to traffic to the nucleus for efficient

273 erferon (IFN-gamma) was tested as a proviral DNA vaccine to extend previous studies showing efficacy

274 allowed an otherwise ineffective therapeutic DNA vaccine to further stimulate antiviral immunity, the

275 four civet S genes were also constructed as DNA vaccines to immunize mice.

276 evolutionize means for effective delivery of DNA vaccines to stimulate mucosal, systemic, and cellula

277 tio to receive a cytomegalovirus therapeutic DNA vaccine (TransVax; Vical, San Diego, CA, USA) or pla

278 The mechanism(s) by which DNA vaccines trigger the activation of Ag-specific T cel

279 VZV DNA (vaccine type) was found in the resected stomach; im

280 A DNA vaccine vector that encodes a domain that contribute

281 eRNA41H was integrated into the backbone of DNA vaccine vectors expressing H5N1 influenza virus hema

282 Administration of DNA vaccines via gene gun has emerged as an important fo

283 gned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by Bio

284 ated immune profile induced by a recombinant DNA vaccine was assessed in the simian/HIV (SHIV) and ma

285 f L. major transmission by P. duboscqi, this DNA vaccine was defined as partially protective, in the

286 and immunogenicity of a first-generation WNV DNA vaccine was demonstrated in a clinical trial and a s

287 The efficacy of the DNA vaccine was enhanced by increasing the level of expr

288 Two consecutive shots of For t 2 DNA vaccine were given to mice with a 7-day interval bef

289 d with a single high dose of Delta4SHIV(KU2) DNA vaccine were monitored longitudinally for vaccine-in

290 DNA vaccines were evaluated using intracellular cytokine

291 e surprisingly, immune responses elicited by DNA vaccines were not cGas-dependent in vivo.

292 tigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe, well tolerated, and immunogenic

293 second-generation, chemokine-fused idiotype DNA vaccines, when combined with myotoxins that induced

294 vaccine, (2) a 3-dose priming regimen of the DNA vaccine with a booster dose of an adenovirus type 5

295 ty and protection, we combined the SIVmac239 DNA vaccine with protein immunization using inactivated

296 This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig)

297 Newborns responded to measles DNA vaccines with similar or even higher PRN titers and

298 ralizing antibody titers than those with the DNA vaccines, with C-prM-E VLPs giving slightly higher t

299 vaccines might enhance the immunogenicity of DNA vaccines without increasing toxicity.

300 cipients against tissue-restricted Ags using DNA vaccines would decrease the risk of relapse without